National Eye Institute

jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell® for Retinitis Pigmentosa in the Second Half of 2024

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Retinitis pigmentosa, National Eye Institute, Doctor of Philosophy, Retina, MD, NIH, FDA, News, Food, Entrepreneurship, RP, Perseverance, UC, Patient, Clinical trial, Type, CMC, Pharmaceutical industry

Additionally, the company is gearing up to commence its pivotal US trial for jCell in the second half of 2024.

Key Points: 
  • Additionally, the company is gearing up to commence its pivotal US trial for jCell in the second half of 2024.
  • Sholar was also delighted with the FDA’s responses to jCyte’s description of its CMC program.
  • “We are pleased with the Type B meeting minutes, which enable us to move forward with the US pivotal trial.
  • The treatment has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and is administered as a minimally invasive intravitreal injection.

Prevent Blindness Launches New "Retinopathy of Prematurity (ROP) Education and Support Program" as Part of Inaugural ROP Awareness Week, Feb. 26 - March 3, 2024

Retrieved on: 
Wednesday, February 21, 2024
Education, Medical director, Medical statistics, Parent, Infant, Pregnancy, University, Organization, Retinopathy, Diagnosis, Gestational age, Head, Social media, Section, Mental health, MBA, Associate professor, MSC, Initiative, Doctor of Psychology, Distribution, Partnership, FACS, National Eye Institute, Ear, University of Illinois Urbana-Champaign, Paratriathlon, ROP, Visual impairment, Safety, Division, MD, Visual Science, Diversity, Patient, Nursing

CHICAGO, Feb. 21, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has launched the new "Retinopathy of Prematurity Education and Support Program," as part of its first ROP Awareness Week, declared Feb. 26 – March 3, 2024. The group is offering a variety of free educational resources to the public and professionals, including fact sheets, social media graphics in English and Spanish, dedicated online resources, and a new video series.

Key Points: 
  • "Diagnosing and treating ROP early is essential for preventing or lessening ROP-associated vision loss," said Jeff Todd, president and CEO of Prevent Blindness.
  • To help address the need for ROP awareness and education, Prevent Blindness convened leading organizations in the parent support, education, and advocacy arenas to partner on creating the ROP Education and Support Program.
  • The ROP Education and Support Program and ROP Awareness Week is supported by funding from Regeneron .
  • In the Prevent Blindness Focus on Eye Health Expert Series, " Retinopathy of Prematurity ," Jeff Todd, president and CEO of Prevent Blindness, interviews R.V.

February Declared as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month by Prevent Blindness

Retrieved on: 
Monday, January 29, 2024
Well, Eye, Patient, Risk, Research, Paratriathlon, Social media, Illinois College of Optometry, Cooking, Diagnosis, Regeneron Pharmaceuticals, Mental, Geographic atrophy, American Academy, Retina, University, Mental health, Disease, Safety, AMD, Johnson & Johnson, Health, Organization, Macular degeneration, Visual impairment, National Eye Institute, Telescopic sight

CHICAGO, Jan. 29, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has declared February as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month. The group is offering a variety of free educational resources to the public and professionals, including fact sheets and social media graphics in English and Spanish, dedicated online resources and informative videos.

Key Points: 
  • Prevent Blindness Provides Free Resources on AMD and Low Vision, Including Fact Sheets, Social Media Graphics, Expert and Patient Videos, An Interactive Patient Guide, and More
    CHICAGO, Jan. 29, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading eye health and safety nonprofit organization, has declared February as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month.
  • Prevent Blindness offers a free printable Amsler grid at https://preventblindness.org/wp-content/uploads/2022/01/Amsler_Grid_2022...
    Additionally, Prevent Blindness offers resources on Geographic Atrophy (GA) , an advanced form of dry AMD.
  • To support those with low vision, and their care partners, Prevent Blindness offers the free comprehensive resource, " Living Well With Low Vision ."
  • As vision loss can sometimes negatively affect mental wellbeing, Prevent Blindness offers the " Vision Loss and Mental Wellness " webpage, as part of the Living Well with Low Vision resource.

iVeena Awarded NEI-SBIR Grant For Progressive Myopia Drug Candidate IVMED-85

Retrieved on: 
Thursday, October 26, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, IND, American Optometric Association, NEI, National Eye Institute, Glaucoma, SBIR, Research and development, Near-sightedness, Doctor of Philosophy, Risk, Retinal detachment, Cornea, Medicinal chemistry, University, Eye, NIH, Cataract

iVeena Delivery Systems Inc. (“iVeena”) , a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research (SBIR) grant of $345,000 for iVeena’s progressive myopia control drug candidate IVMED-85.

Key Points: 
  • iVeena Delivery Systems Inc. (“iVeena”) , a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research (SBIR) grant of $345,000 for iVeena’s progressive myopia control drug candidate IVMED-85.
  • Myopia generally first occurs in school-age children and progresses as the eye grows.
  • IVMED-85 is an experimental topical eye drop that is designed to be administered twice-daily to slow the progression of myopia in children.
  • Dr. Molokhia added that “The NIH and NEI have been extremely supportive of our topical eye drop for treatment of progressive myopia.

Prevent Blindness Provides Informational Resources to Professionals and the Public for November's Diabetes-related Eye Disease Awareness Month

Retrieved on: 
Wednesday, October 25, 2023
UnitedHealth Group, Social media, Population health, US, American Diabetes Association, Diabetic retinopathy, Prevalence, Health, Mental, Disease, Risk, Eye, Public, Paratriathlon, Potential, Retina, Parent, Mental health, MHS, Yale School of Medicine, Organization, Prediabetes, National Eye Institute, CDC, Centers for Disease Control and Prevention, Vision, VSP Vision Care, Research, JAMA Ophthalmology, Visual impairment, Microsoft PowerPoint, Research to Prevent Blindness, MBA, Database, Johns Hopkins School of Medicine, Associate, Pharmaceutical industry, Ophthalmology, Regeneron Pharmaceuticals, MD, Diabetes

CHICAGO, Oct. 25, 2023 /PRNewswire-PRWeb/ -- A recent study, "Prevalence of Diabetic Retinopathy in the US in 2021," estimated that more than 26 percent of people with diabetes had diabetic retinopathy. Diabetic retinopathy, the most common form of diabetes-related eye disease, is the leading cause of blindness in adults age 20–74, according to the National Eye Institute.

Key Points: 
  • Diabetic retinopathy, the most common form of diabetes-related eye disease, is the leading cause of blindness in adults age 20–74, according to the National Eye Institute .
  • The longer a person has diabetes, the greater the risk for diabetes-related eye disease.
  • Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has declared November as Diabetes-related Eye Disease Awareness Month, providing the public with a variety of helpful tools to prevent unnecessary vision loss from diabetes.
  • Vision Integration Library - The Center for Vision and Population Health at Prevent Blindness offers the free "Vision Integration Library: Vision and Eye Health Resource Center at Prevent Blindness."

LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration

Retrieved on: 
Wednesday, September 27, 2023
Professional Services, Medical Devices, Health, Small Business, Clinical Trials, Optical, Retina, Small business, Vance DeGeneres, NEI, AMD, SBIR, Duke University School of Medicine, Geographic atrophy, Intravitreal injection, GA, Ophthalmology, HIV disease progression rates, Patient, National Eye Institute, OCT, PBM, Knowledge, NIH, National Institutes of Health Clinical Center, Disease, Pharmaceutical industry

The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial.

Key Points: 
  • The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial.
  • LIGHTSITE IIIB will treat patients for 4 rounds of treatment over fourteen months.
  • Sham patients in the previous study will be able to cross over and begin PBM treatment.
  • “We are excited to have the NIH/NEI partially support the further development endeavors of LumiThera as we bring the therapy to U.S. patients.”

Eye Care Organizations Unite to Save Sight of Premature Infants Using Artificial Intelligence

Retrieved on: 
Thursday, September 21, 2023
Retina, Telehealth, Partnership, National Eye, Life, DL, Oregon Health & Science University, Oxygen, Ophthalmology, Research, Paratriathlon, Eye, Patient, Premature, Orbis International, Risk, Child, SUNY Downstate Health Sciences University, ROP, Artificial intelligence, Diagnosis, National Eye Institute, FDA, National Institute for Health and Care Excellence, Disease, Pharmaceutical industry, Nursing, Birth control, Medical device, Orbis, AI

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Eye care nonprofit Orbis International is excited to announce a new strategic partnership with Siloam Vision to use the company's cloud-based telemedicine platform to expand access to eye care and prevent blindness in premature infants living in hard-to-reach communities. Siloam Vision's artificial intelligence (AI) platform helps diagnose retinopathy of prematurity (ROP) – the leading cause of childhood blindness globally.

Key Points: 
  • Siloam Vision's artificial intelligence (AI) platform helps diagnose retinopathy of prematurity (ROP) – the leading cause of childhood blindness globally.
  • Orbis and Siloam Vision have aligned missions to make sure no child starts out life blind from an avoidable cause.
  • We are excited to partner with Orbis to help save the sight of more preterm babies in hard-to-reach-communities."
  • Orbis is working to ensure eye care professionals everywhere can access these tools for free.

NDRI Receives $3.7 Million Grant from NIH to Continue the Development of NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program

Retrieved on: 
Wednesday, September 6, 2023
Science, Stem Cells, Other Science, Biotechnology, Research, Health, Hospitals, Genetics, NIDDK, Tissue, National Disease Research Interchange, Division of Program Coordination, Planning, and Strategic Initiatives, National Institute of Allergy and Infectious Diseases, Partnership, Arthritis, NEI, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Heart, Lung, and Blood Institute, Skin condition, Lung, Bangladesh Technical Education Board, MS, NHLBI, Kidney, NIAMS, National Eye Institute, National Institute of Diabetes and Digestive and Kidney Diseases, NDRI, Human musculoskeletal system, NIAID, Digestive, NIH, Infection, Pharmaceutical industry, Management

This new three-year award for NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program parent grant extends the NIH’s ongoing funding support for HTORR to 35 consecutive years.

Key Points: 
  • This new three-year award for NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program parent grant extends the NIH’s ongoing funding support for HTORR to 35 consecutive years.
  • The HTORR Program supports investigators across the full spectrum of research with access to normal and diseased human biospecimens.
  • “NDRI is grateful to the NIH for the support of our expanding HTORR program,” said Bill Leinweber, President and CEO of NDRI.
  • This grant renewal includes multiple enhancements such as a new Pilot Program, Pathology Service Options, and a Pathology Consultant Committee.

New Data from Prevent Blindness Shows More than 32,000 Sports-related Eye Injuries were Treated Last Year, an almost 20 Percent Increase Over the Previous Year

Retrieved on: 
Tuesday, August 29, 2023
Sport, Education, Visual impairment, Blunt trauma, Research to Prevent Blindness, OD, Skiing, Eye, USC, Snow, Parent, Athlete, Social media, Risk, National Eye Institute, Child, Water, Abrasion, Eye injury, Paratriathlon, Injury, Personal protective equipment, Telescopic sight, Tutoring, Optometry

CHICAGO, Aug. 29, 2023 /PRNewswire-PRWeb/ -- New annual data from Prevent Blindness, the nation's leading eye health nonprofit organization, shows that there were more than 32,000 sports-related eye injuries treated in the United States last year, an increase of almost 20 percent from the previous year. To educate the public on the risk of significant and potentially blinding eye injuries and the need for proper eye protection, Prevent Blindness has declared September as Sports Eye Safety Month.

Key Points: 
  • To educate the public on the risk of significant and potentially blinding eye injuries and the need for proper eye protection, Prevent Blindness has declared September as Sports Eye Safety Month.
  • "A sports-related eye injury can happen in an instant, but the effects may last a lifetime," said Jeff Todd, president and CEO of Prevent Blindness.
  • The new Prevent Blindness data showed once again that the category of "non-powder guns, darts, arrows, and slingshots" had the overall highest rate of eye injuries.
  • Types of sports-related eye injuries include blunt trauma, penetrating injuries, eye infections, and corneal scratches and abrasions.

Dr. Evan Schoenberg Becomes The First Doctor In Georgia to Implant the IC-8® Apthera™ IOL

Retrieved on: 
Thursday, August 17, 2023
Optical, Health, Surgery, Medical Devices, Retina, Eye, Ageing, National Eye Institute, GLARE, IOL, Astigmatism, Patient, Face, Refraction, Hospital, Telescopic sight, Atlanta

Georgia Eye Partners is proud to share that Dr. Evan Schoenberg has become the first eye surgeon in the Atlanta metro area to implant the Apthera IOL, the first and only small aperture lens for cataract surgery.

Key Points: 
  • Georgia Eye Partners is proud to share that Dr. Evan Schoenberg has become the first eye surgeon in the Atlanta metro area to implant the Apthera IOL, the first and only small aperture lens for cataract surgery.
  • Some patients receive a monofocal IOL, which provides clear distance vision but leaves objects up close blurry.
  • The Apthera IOL is intended for use in just one eye and is paired with a monofocal or monofocal toric (astigmatism-correcting) IOL in the fellow eye.
  • Georgia Eye Partners remains committed to serving the growing aging population throughout Greater Atlanta and Georgia by implementing the latest and greatest advanced cataract surgery technologies and procedures.